NEW YORK — Exagen reported on Tuesday a 15 percent year-over-year drop in its second quarter revenues on lower testing revenue.
For the three-month period ended June 30, Exagen's revenues were $8.9 million versus $10.5 million a year earlier, topping the consensus Wall Street estimate of $4.7 million. Testing revenue dropped 33 percent to $6.8 million year over year from $10.2 million, which the San Diego-based autoimmune diagnostics company attributed to lower testing volumes amid the SARS-CoV-2 pandemic and a decrease in average reimbursement per test.